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Dissecting the crosstalk between tumor cells and tumor microenvironment is quickly
becoming the new frontier in cancer research. It is now widely accepted that cancer cells
can exert a profound influence over their surroundings, by changing themicroenvironment
from a normal to a tumor-supportive state that allows for sustained tumor growth,
invasion, and drug resistance. Extracellular vesicles, especially exosomes, are recognized
as a new category of intercellular communicator, and they are emerging as of primary
importance in controlling the interplay between the tumor and its environment. Exosomes
derived from cancer cells or from cells of the tumor microenvironment allow for the
horizontal transfer of information by virtue of their cargo, made of functional proteins and
nucleic acids that are specifically sorted and loaded in exosomes during their biogenesis.
In this review, we will discuss the current knowledge regarding the role invested by
microRNAs, a family of short non-coding RNAs frequently deregulated in malignancies
and present in exosomes, in shaping the microenvironment in a cancer-dependent
manner.
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Introduction
While great advances have been made in the fight against cancer, it is still a leading cause of death
in the twenty-first century, and a deeper understanding of the biology of the cancer cells and their
surrounding is needed in order to develop novel therapeutic strategies. In the past three decades,
researchers and clinicians have mostly focused on the identification of cancer-specific targets and
the development of targeted therapies that could efficiently kill the cancer cells while sparing their
normal counterpart, therefore reducing unwanted side effects. This global effort has resulted in
the development of a number of promising and highly effective small molecules targeting cancer-
specific alterations and/or altered signal transduction pathways that control the proliferation and
survival of cancer cells (1). Moreover, a series of monoclonal antibodies have been developed, and
FDA approved, to exploit the preferential and/or enhanced expression of antigens on the surface of
malignant cells (e.g., ERBB2 in breast cancer, CD20 or CD52 in chronic lymphocytic leukemia)
and to allow the specific modulation of survival pathways (when utilized as naked antibodies),
or the targeted delivery of a toxic payload (when utilized as conjugated antibodies) (2). Although
this approach has proven effective and promising in some cases, there are obvious drawbacks;
first, because of the clonal evolution of malignant cells, cancers are characterized by extensive
heterogeneity and a variety of subtypes that makes it difficult to identify unique targets and to
eradicate the totality of tumor cells; second, it is important to remember that the growth of a tumor
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may also be influenced by its own surroundings and the host
organism as a whole. Indeed, there is increasing evidence that
the interaction between tumor cells and components [i.e., stromal
cells, immune cells, and extracellular matrix (ECM)] of the sur-
rounding tumormicroenvironmentmay directly affect the growth
and the drug resistance of the primary tumor and also control its
evolution from early to late/metastatic stages.
The Tumor Microenvironment
The tumor microenvironment is defined as the variety of nor-
mal cells, blood vessels, signaling molecules, and ECM that sur-
round the tumor cells. The cellular components of the tumor
microenvironment include endothelial cells, pericytes, fibroblasts,
and immune cells (3). Importantly, one of the first mechanisms
of interaction between the tumor and the microenvironment to
receive considerable attention was the discovery that tumors can
secrete factors (e.g., VEGF) that act on neighboring endothe-
lial cells resulting in the formation of new blood vessels able
to support the continuous growth and the metastatic potential
of the tumor itself (3). Tumor-associated immune cells are also
important components of the tumormicroenvironment; in partic-
ular, tumor-associated macrophages (TAMs) have been reported
to be frequently detected in close proximity of tumors or infil-
trating its stroma (4). Interestingly, solid tumors can be strat-
ified based on the level of TAM infiltration, and high levels
of TAMs frequently correlate with enhanced metastatic poten-
tial, increased vascularization, and overall poor prognosis (4).
Indeed, naturally occurring TAMs are generally skewed toward
an M2-like activated phenotype (CD68+, CD163+), and display
overall pro-tumorigenic and pro-angiogenic activities, suggest-
ing that persistent inflammation at the tumor site may con-
tribute to tumorigenesis (3, 5, 6). Other tumor microenvironment
components, cancer associate fibroblasts (CAFs), mesenchymal
stem/stromal cells (MSCs), cancer-associated adipocytes (CAAs),
and the ECM, also play a role in supporting cancer cell growth
and dissemination (7). In particular, CAFs and MSCs in the
tumor microenvironment exist in a pro-inflammatory state and
secrete inflammatory chemokines and growth factors (i.e., CCL2,
CXCL8, CCL5, FG9) with known pro-tumorigenic functions (8,
9). CAAs and CAFs also contribute to structural remodeling
of the ECM, through aberrant deposition of collagen, laminin,
fibronectin, and secretion of matrix metallo-proteases (MMPs),
hence supporting not only local tumor growth but also basal
membrane invasion and cancer cell metastasis (7). Like TAMs,
high infiltration of perpetually activated pro-inflammatory CAFs
and CAAs has been linked to poor prognosis in several malig-
nancies, such as non-small cell lung cancer (NSCLC) and breast
cancer (7). Importantly, it is becoming evident that the cross-
talk between cancer cells and tumor microenvironment has a
fundamental role in inducing and maintaining drug resistance
even in the absence of tumor-specific alterations [reviewed in
Ref. (10)]. Tumor microenvironment-associated mechanisms of
drug resistance include, but are not limited to, elevated pro-
duction of growth factors (e.g., HGF) that induce the activation
of survival pathways that are not targeted by current therapies
[e.g., stimulation of MET receptor by HGF in melanoma cells
harboring the mutated form of BRAF(V600E) (11)]; the recruit-
ment of pro-tumorigenic immune cells to the tumor sites elicited
by the treatment itself and leading to worse prognosis (12); tumor
microenvironment-dependent hypoxia, and high interstitial fluid
pressure that may induce cell survival genes and inhibit the dis-
tribution of drugs to the tumor site(13). Based on numerous
recent studies and on the increased interest in the tumormicroen-
vironment, it has become apparent that targeting not only the
cancer cells but also their surroundings may be a novel thera-
peutic strategy to overcome current limitations. In this regard, it
is important to investigate the mechanisms by which the tumor
cells can “educate” the surrounding environment to transition
from “normal” to pro-inflammatory and pro-tumorigenic. In this
scenario, understanding the cross-talk between tumor cells and
tumor microenvironment has become of paramount importance.
Alongside with other well-known pathways by which cells can
communicate (e.g., paracrine and endocrine signaling, adhesion
molecules, cell junctions), considerable attention is now being
given to the role of extracellular vesicles (EVs) and their protein
and nucleic acid cargo. Importantly, EVs allow for the horizon-
tal transfer of information between cells and may account for
the existence of tumor-specific genetic alterations in the tumor
microenvironment (14).
Extracellular Vesicles and Their
Payload: microRNAs as Intercellular
Communicators and Cancer Biomarkers
Extracellular vesicles represent a class of circulating cellular frag-
ments, other than apoptotic bodies that can be identified based
on their size, generally ranging from 30 nm to a fewmicrons, their
density, and the presence of a bilayer lipidicmembrane resembling
the plasma membrane. The universally recognized categories of
EVs are (1) exosomes, with a size of approximately 30–100 nm
and a density of 1.13–1.19 g/ml, (2) microvesicles (also known as
ectosomes), a more heterogeneous and less characterized group
with sizes ranging from 100 to 1000 nm and with a lower density
than exosomes, and (3) the more recently discovered “large onco-
somes,” derived from bulky cellular protrusions, ranging approx-
imately 1–10μm in size (15, 16). Although current purification
methods do not always allow for the precise separation of larger
exosomes and smaller microvesicles due to their sometime over-
lapping size, their biogenesis is profoundly different (15). While
microvesicles originate directly from an outward budding of the
plasma membrane and intracellular space, exosomes undergo
active packaging in intracellular endosomes, which evolve into
multivesicular bodies as a consequence of inward budding of the
plasma membrane, and then are either targeted to the lysosomes
for degradation or released in the extracellular milieu after fusion
with the membrane (Figure 1) (14, 15). Released exosomes can
then be targeted to other cells through a very specific yet poorly
understood mechanism, likely involving surface proteins, such
as tetraspanins and adhesion molecules (15); nonetheless, the
exosomes are taken up by the target cells through direct mem-
brane fusion or endocytosis and can be directed to lysosomes for
degradation, or their cargo can be released inside the recipient
cells (Figure 1) (15). Indeed, all EVs have been shown to contain
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FIGURE 1 | Schematic representation of the biogenesis of exosomes and the cross-talk between cancer cells and the cells of the tumor
microenvironment. MVB, multivesicular body; Lys, lysosome; EMT, epithelial-to-mesenchymal transitions; Exo, exosomes.
a specific payload of fully functional proteins and nucleic acids in
the form ofmRNAs, microRNAs, and long non-coding RNAs (14,
15). In this review, we focus on the role of exosomal microRNAs.
MicroRNAs represent a large and ever-growing family of small
non-coding RNAs (19–24 nucleotides) that have the ability to
deeply control gene expression by recognizing target sequences
usually on, but not limited to, the 30-UTR of specific mRNAs.
Partial complementarity of the miRNA sequence to its target
will prime the mRNA for degradation or, more frequently, will
impede its translation, generally resulting in down-regulation of
the encoded protein, although it has been reported that in a few
cases, a microRNA may induce higher translation rate of specific
mRNAs (14). Since a single microRNA can have multiple targets
and a specific mRNA can be targeted by several microRNAs,
these small nucleic acids have emerged as fundamental global
regulators of gene expression and their levels are frequently altered
in cancers and other diseases (14). Importantly, the discovery
that exosomes carry a non-random cargo of miRNAs and that
they can deliver their content to target cells, raised the fascinating
possibility that such ubiquitous nanoparticles could work as a
novel category of intercellular communicators both in a paracrine
and endocrine fashion (14, 17, 18); the delivery of fully functional
miRNAs derived from cancer cells would have the ability of pro-
foundly influence the gene expression of other normal cells both
in close proximity, molding the surrounding microenvironment
into a cancer-growth permissive milieu, and in distant organs, by
possibly transforming a normal site into a pre-metastatic niche.
Moreover, since cancer-derived exosomes can be detected in all
body fluids, one of the first practical applications in this regard
was to exploit their presence as novel non-invasive biomarkers for
cancer diagnosis as the expression of specificmiRNA families, also
known as oncomiRs, is frequently enhanced in several cancers
(e.g., miR-155, miR-21, the miR-17–92 cluster, miR-210, miR-
16) and their altered expression can be detected in serum from
cancer patients when compared to healthy individuals (3, 19).
Importantly, changes in the expression of such miRNAs dur-
ing treatment have also been proposed as a tool for monitoring
therapy effectiveness and risk of relapse (3, 19).
Several groups have reported that the loading of proteins and
nucleic acids is an active mechanism that requires sorting of
specific molecules into the multivesicular bodies where exosomes
are being assembled, in a process that is still poorly understood.
The current knowledge regarding the loading of proteins through
Endosomal Sorting Complexes Required for Transport (ESCRT)
and tetraspanin-dependent and -independent mechanisms has
been reviewed in Ref. (17). Concerning the loading of microRNA
molecules, there is some evidence that the recognition of two
different 4-nucleotide motifs by the sumoylated RNA-binding
protein hnRNPA2B1 may play a role in the sorting of specific
microRNAs into exosomes, and that the availability ofmicroRNAs
free to be loaded into exosomes may also be dictated by the abun-
dance of their endogenous RNA targets (i.e., mRNA and other
non-codingRNAs) that can therefore act asmiRNA “sponges” (17,
18). Interestingly, it has been recently reported that microRNAs
can also be found in their precursor state (pre-miRNA) associated
to its processing complex (e.g., Dicer, Ago2, and TRBP) inside
breast cancer-derived exosomes, where they can be processed into
mature microRNAs (20).
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Molding of the Microenvironment by
Exosomal MicroRNAs: A Two-Way
Communication Highway Between Cancer
Cells and Their Surroundings
The natural evolution of cancer cells is a multistep process that
requires acquisition of growth and survival advantage but also the
ability to interfere with the surrounding, shaping the microenvi-
ronment into a pro-inflammatory and pro-tumorigenic niche. It
is becoming more and more evident that in order to deeply take
control over their neighboring normal cells, cancer cells utilize
exosomes, which, at least in part, by virtue of their miRNA-
cargo, can alter their behavior and induce cancer-promoting func-
tions, such as proliferation, ECM remodeling, migration, inva-
sion, angiogenesis, and metastatic process (Figure 1) (21). It has
been shown that exosomal miRNAs can affect cells of the tumor
microenvironment both in a canonical (mRNA-targeting) and
non-canonical (receptor-binding)manner (6).Wehave previously
reported that NSCLC secretes an abundance of exosomes contain-
ing miR-21 and miR-29a and that these particles are released in
the microenvironment and taken up by surrounding TAMs and
transferred to their endosomes (6). When the exosomal cargo
is released, these miRNAs are able to directly bind and activate
the endosomal TLR8 receptor (homologous of TLR7 in mice)
and induce NF-κB-dependent transcription, this resulting in the
expression of the pro-inflammatory cytokines IL-6 and TNF-α
that support the growth of NSCLC and its metastatic potential
(Table 1) (6). This was the first report of a miRNA to be able to
directly activate a receptor. Moreover, we have recently uncovered
that a similar mechanism of “education” of TAMs occurs also in
the neuroblastoma (NBL) microenvironment and contributes to
the development of drug resistance (5). NBL-derived exosomes
carry and transfer miR-21 into neighboring monocytes where it
activates the TLR8 receptor and induces NF-κB-dependent tran-
scription ofmiR-155, an oncomiR found frequently overexpressed
in cancer (Table 1) (5). Importantly, miR-155 is then shuttled back
to the NBL cells packaged in TAM-derived exosomes where it
directly targets the mRNA of the inhibitor of telomerase TERF1,
resulting in alteration of telomerase activity, telomere length, and
overall acquisition of increased resistance to cisplatin (CDDP)
treatment. This study raises the intriguing possibility that the
frequent increase in expression of miR-155 in solid tumors may
be, at least in part, due to the presence of pro-tumorigenic immune
cells in the tumor stroma rather than being expressed by the tumor
cells themselves. Interestingly, signaling through themurine TLR7
receptor activated by miR-21 delivered by cancer exosomes has
also been described to induce cell death of mouse myoblasts
(22). This recent observation supports a potential role of exo-
somes in inducing cancer-associated cachexia, a debilitating mus-
cle wasting syndrome frequently observed in the skeletal muscles
of advanced stage cancer patients (22). One of the fundamental
characteristics in the evolution of cancer is the ability to invade
the microenvironment and give rise to distant metastasis. The
epithelial-to-mesenchymal transition (EMT) represents a critical
step of tumor progression and malignant transformation, during
which cancer cells detach from the primary tumor site, acquire
increased motility and the ability to invade the local ECM, fol-
lowed by extravasation into the bloodstream for dissemination to
distant organs (23). The role of intercellular communication for
the regulation of EMT and for the induction and maintenance of
a pre-metastatic cancer phenotype has been the subject of several
studies and the role of exosomal miRNAs has emerged. For exam-
ple, exosomal miR-223 is transferred from macrophages to breast
cancer cells and promotes invasion through down-modulation of
the Mef2c/β-catenin pathway (Table 1) (24). Transfer of cancer-
derived exosomal miR-105 to endothelial cells has been shown
to disrupt the vascular endothelial barrier (i.e., by targeting the
tight junction protein ZO-1) during early breast pre-metastatic
niche formation (Table 1) (25). Another group has shown that
tumor-derived exosomal miR-494 and miR-542-3p were able
to modify distant lymph nodes and lung tissue toward a pre-
metastatic phenotype suitable for tumor cell hosting, by targeting
cdh17 and MAL, and cdh17 and TRAF4, respectively (Table 1)
(26). It has recently been shown that an exosome-mediated
TABLE 1 | Exosomal microRNAs shuttling between cancer cells and tumor microenvironment.
miRNA From To Target Effect on TME Reference
miR-21 NSCLC TAM TLR8 * Growth and metastasis (5, 6, 22)
NBL TAM * miR-155
Lung or pancreatic cancer Myoblasts * Cachexia
miR-29a NSCLC TAM TLR8 * Growth and metastasis (6)
miR-155 TAM NBL TERF1 * Drug resistance (5)
miR-223 TAM Breast cancer Mef2c * Invasion (24)
miR-105 Breast cancer Endothelial cells ZO-1 + Tight junctions (25)
miR-494 Adenocarcinoma Lymph nodes MAL; cdh17 * Pre-metastatic phenotype (26)
Lung
miR-542-3p Adenocarcinoma Lymph nodes Cdh17; TRAF4 * Pre-metastatic phenotype (26)
Lung
miR-503 Endothelial cells Breast cancer N/A + Angiogenesis (27)
miR-10b Metastatic breast cancer Non-metastatic breast cancer HOXD10; KLF4 * Metastasis (28)
miR-200 Metastatic breast cancer Non-metastatic breast cancer ZEB1; ZEB2 * Metastasis (29)
miR-135 Multiple myeloma Endothelial cells FIH-1 * Angiogenesis (31)
miR-34a MSC Breast cancer N/A * Growth (32)
NSCLC, non-small cell lung cancer; NBL, neuroblastoma; TAM, tumor-associated macrophages; MSC, mesenchymal stem/stromal cells.
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cross-talk between endothelial cells and breast cancer cells can
modulate angiogenesis and tumor growth (27). When HUVEC
cells were co-cultured with breast cancer cells (i.e., MDA-MB-
231 cells), exosomes derived from endothelial cells showed lower
levels of the anti-angiogenic and tumor-suppressive miR-503;
while it is not clear how the cancer cells were inducing this change
in the endothelial cells, this report highlights a mechanism by
which a tumor can silence anti-tumorigenic factors normally
secreted by the microenvironment (Table 1) (27). Exosome-
associated miRNAs are also involved in the metastatic potential
of breast cancer; in fact, it has been shown that metastatic MDA-
MB-231 breast cancer cells produce exosomes with higher levels
of miR-10b than non-metastatic MCF-7; interestingly, when non-
malignant breast epithelial HMLE cells were exposed to exosomal
miR-10b, they acquired a more invasive phenotype (Table 1) (28).
In a similar fashion, EVs derived from metastatic breast cancer
cells were shown to be able to transfer their metastatic potential
through delivery of miR-200 to non-metastatic cells (29). These
observations are in line with another previous study showing that
exosomes can transfer the metastatic activity of highly metastatic
BL6–10 melanoma tumor cells to poorly metastatic F1 melanoma
tumor cells in vitro (30). Exosomal miRNAs have also been shown
to be able to induce angiogenesis under hypoxic conditions typical
of the bonemarrowmicroenvironment; in fact, multiple myeloma
cells grown under chronic hypoxic conditions produce a higher
amount of exosomes than cells cultured in normoxic conditions;
furthermore, their exosomes had higher levels of miR-135b that,
when transferred to surrounding endothelial cells, targets the
HIF-1α inhibitor FIH-1 and results in enhanced endothelial
tube formation and angiogenesis (Table 1) (31). Several studies
have also reported that human mesenchymal/stromal cells
(hMSCs) create a tumor-supportive microenvironment, and a
recent important report sought to investigate the contribution
of their secretome on their pro-tumorigenic potential (32).
Specifically, the composition of the cargo of hMSC-derived
exosomes was characterized by next generation sequencing
and proteomic analysis. The authors found that hMSC exo-
somes carry a large number variety of tumor-supportive pro-
teins (e.g., PDGFR-b, TIMP-1, and TIMP-2) and of miRNAs
(e.g., miR-21 and miR-34a) that exhibited pro-tumorigenic
functions when expressed in MCF-7 breast cancer cells
(Table 1) (32).
Conclusion
In order to successfully develop advanced therapeutic options
for the treatment of cancer, it is becoming increasingly apparent
that one cannot disregard the role of the tumor microenviron-
ment. As outlined in this review, the tumor and its surroundings
embody a dynamic environment in which cancer cells orchestrate
the alteration of exosome-dependent signals that “educate” the
microenvironment to act in a pro-tumorigenic fashion. Under-
standing this cross-talk is of tremendous importance; in fact, one
can envision that in the near future, we will be able to counteract
pro-tumorigenic and pro-metastatic signals that contribute to the
growth, spreading, and drug resistance of tumor cells by poten-
tially engineering the miRNA and protein cargo of exosomes or
by interfering with their trafficking.
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